Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of Transdermal Fentanyl PCA and IV Morphine PCA in the Management of Postoperative Pain Control.

Trial Profile

Comparison of Transdermal Fentanyl PCA and IV Morphine PCA in the Management of Postoperative Pain Control.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fentanyl (Primary) ; Morphine
  • Indications Postoperative pain
  • Focus Registrational; Therapeutic Use
  • Acronyms EuroTrans
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 25 Sep 2015 According to The Medicines Company media release, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending marketing authorization for IONSYS for treatment of poost-operative pain in adult patients.
    • 30 Apr 2015 According to The Medicines Company media release, company has received USFDA approval for IONSYS.
    • 23 Oct 2009 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top